Biotech Values

[genisi]

(e.g., TTR >~68%, near the midpoint of center based TTR in the RE-LY study, and the US median TTR of 65% in ROCKET).

Made me check the data from the ARISTOTLE trial and it had a "median TTR of 65.7% (interquartile limits 58.0% and 72.2%). Across centres’ TTR quartiles there were consistently lower rates of stroke and systemic embolism and major bleeding with apixaban than warfarin. In the lowest and highest centres’ TTR quartiles, hazard ratios (HR) were respectively 0.77 (95%CI 0.56 – 1.06) and 0.81 (95%CI 0.52 - 1.26) for stroke or systemic embolism and 0.53 (95%CI 0.39 - 0.72) and 0.72 (95%CI 0.55 - 0.93) for major bleeding."

http://www.escardio.org/congresses/esc-2011/congress-reports/Pages/709-3-ARISTOTLE.aspx